Bonesupport Holding Ab · OMXSTO:BONEX
Bonesupport Holding Ab — Q3 2019 Earnings Presentation
17 slides from Bonesupport Holding Ab's earnings presentation, November 2019
Slide 1: BONESUPPORT Q3(19)
BONESUPPORT™ Q3(19) November 2019 Emil Billbäck, CEO Håkan Johansson CFO
Slide 2: Disclaimer
DISCLAIMER This presentation, which includes all information and data on the following slides, any oral statements made when presenting these slides, and any other material distributed or statements made at, or in connection with, such presentation (the “Presentation”), relates to BONESUPPORT HOLDIN
Slide 3: Financial highlights / Operational highlights
Financial highlights • Q3(19) net sales SEK39.1m • EU & ROW: +45% Y/Y to SEK20.7m • CERAMENT G & V: +44% • North America: Q/Q growth with +25% • Gross margin: 88%, improvement fourth quarter in a row Operational highlights • Signed contract with HealthTrust • Strong progress in US market access • Ne
Slide 4: New all time high - Strong growth in both regions
New all time high - Strong growth in both regions 4
Slide 5: EUROW – Continued momentum, showing strong sales growth
EUROW – Continued momentum, showing strong sales growth Q3 2019 • Total sales of SEK20.7m, growth of 45% • Antibiotic eluting products growth of 44% Highlights • Top line results from CERTiFy driving use of CERAMENT in favour of autograft. CERTiFy accepted for publication in Journal of bone and Join
Slide 6: North America – Biggest national GPO contract awarded
North America – Biggest national GPO contract awarded Q3 2019 • Total sales of SEK18.5m, 25% growth Q/Q (19) • First quarter without Zimmer Biomet field sales activities Strong progression with GPO contracts signed • HealthTrust, the largest national GPO with 1600 hospitals • GPO sales should have s
Slide 7: Favourable health economic data for CERAMENT G&V – first results
Favourable health economic data for CERAMENT G&V – first results Nuffield Orthopaedic Centre, Oxford University Hospitals - one of the leading clinics in Europe in orthopedics and treatment of bone infections Clinical data Health economic data, top line results In 2013 Nuffield introduced CERAMENT G
Slide 8: Financial Review
Financial Review
Slide 9: Q3(19) net sales SEK39.1m – All time high
Q3(19) net sales SEK39.1m – All time high +175% Net Sales Q3 9
Slide 10: North America – Showing strong growth Q/Q
North America – Showing strong growth Q/Q Jul - Sep (SEKm) 2019 2018 Net Sales 18.5 0.0 Gross profit 16.9 0.0 Net sales Contribution -9.8 -20.2 Q3 SEK18.5m +25% Net Sales Q/Q 10
Slide 11: EUROW – strong Y/Y growth
EUROW – strong Y/Y growth Jul - Sep (SEKm) 2019 2018 45% Net Sales 20.7 14.2 Net Sales Gross profit 17.4 11.7 Q3 Contribution 0.6 -3.9 11
Slide 12: Well funded to profitability
Well funded to profitability Key Figures 2019 2018 2017 SEK m Q3 Q2 (ii) Q1 Q4 Q3 (i) Q2 Q1 Q4 Net Sales 39.1 37.3 32.8 23.1 14.2 28.2 31.1 27.0 Gross Margin (%) 87.7 86.5 85.9 85.0 81.8 87.4 82.1 83.3 Operating Loss -32.7 -47.8 -39.0 -45.0 -58.4 -37.8 -33.1 -33.4 Cash at period end 129.9 173.1 219.
Slide 13: Focused investments in commercial acceleration
Focused investments in commercial acceleration Key Figures 2019 2018 2017 SEK m Q3 Q2 (i) Q1 Q4 Q3 Q2 Q1 Q4 Selling expenses 39.5 52.7 40.8 38.8 35.1 31.8 27.6 21.5 Research and 17.4 16.0 16.9 17.6 16.4 17.2 14.8 19.7 Development expenses Administrative expenses 10.9 10.5 10.4 9.3 17.5 14.9 16.5 15.
Slide 14: Clear Corporate Strategy Driving Value Creation
Clear Corporate Strategy Driving Value Creation
Slide 15: Delivering on updated strategy
Delivering on updated strategy • Expect a good Q4 2019 and strong momentum going into 2020 ‒ Improved market access in the US – better coverage of indications, states and GPOs ‒ HealthTrust, biggest and most important GPO contract ‒ Expanded European sales team making impact in under-penetrated regi
Slide 16: CERAMENT Value generating milestones
CERAMENT® Value generating milestones 20:e May ZB Q3 2019 Q3 2020 2021 Q1 2019 ceases to sell CERAMENT®|G CERAMENT® G CERAMENT® G BONIFY Launch CERAMENT Canada Launch Australia Launch PMA application 2019 2020 2021 2022 Q1 2019 H1 2020 Q4 2019 2021: 2022 SOLARIO FORTIFY last Health Economic FORTIFY
Slide 17: Q&A
Q&A